Insider Selling: Entellus Medical Inc (ENTL) VP Sells 2,449 Shares of Stock

Entellus Medical Inc (NASDAQ:ENTL) VP Thomas P. Williamson sold 2,449 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $24.08, for a total transaction of $58,971.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Thomas P. Williamson also recently made the following trade(s):

  • On Friday, January 5th, Thomas P. Williamson sold 968 shares of Entellus Medical stock. The shares were sold at an average price of $24.01, for a total transaction of $23,241.68.

Shares of Entellus Medical Inc (NASDAQ ENTL) traded down $0.08 during trading hours on Tuesday, hitting $24.28. 134,509 shares of the stock traded hands, compared to its average volume of 246,683. The firm has a market capitalization of $618.51 and a P/E ratio of -18.97. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 52 week low of $11.47 and a 52 week high of $25.58.

ENTL has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Monday, October 9th. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Canaccord Genuity reiterated a “hold” rating and set a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Finally, William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $19.25.

Several large investors have recently made changes to their positions in the company. Neuberger Berman Group LLC increased its holdings in shares of Entellus Medical by 152.2% during the third quarter. Neuberger Berman Group LLC now owns 58,000 shares of the medical technology company’s stock worth $1,071,000 after buying an additional 35,000 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Entellus Medical by 74.7% during the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after buying an additional 4,846 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Entellus Medical during the third quarter worth $302,000. Archon Capital Management LLC increased its holdings in shares of Entellus Medical by 14.9% during the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock worth $10,157,000 after buying an additional 71,404 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Entellus Medical by 145.1% during the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after buying an additional 5,605 shares in the last quarter. Institutional investors own 78.76% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Entellus Medical Inc (ENTL) VP Sells 2,449 Shares of Stock” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/10/insider-selling-entellus-medical-inc-entl-vp-sells-2449-shares-of-stock.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply